Canagliflozin for Japanese patients with chronic heart failure and type II diabetes.
Adiposity
/ drug effects
Aged
Aged, 80 and over
Atrial Natriuretic Factor
/ blood
Biomarkers
/ blood
Blood Glucose
/ drug effects
Canagliflozin
/ adverse effects
Chronic Disease
Diabetes Mellitus, Type 2
/ diagnosis
Female
Heart
/ drug effects
Heart Failure
/ diagnosis
Humans
Japan
Kidney
/ drug effects
Male
Middle Aged
Natriuretic Peptide, Brain
/ blood
Prospective Studies
Sodium-Glucose Transporter 2 Inhibitors
/ adverse effects
Time Factors
Treatment Outcome
Weight Loss
/ drug effects
Diabetes
Heart failure
SGLT2 inhibitor
Journal
Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637
Informations de publication
Date de publication:
05 06 2019
05 06 2019
Historique:
received:
27
03
2019
accepted:
29
05
2019
entrez:
7
6
2019
pubmed:
7
6
2019
medline:
25
2
2020
Statut:
epublish
Résumé
Reports that sodium glucose cotransporter 2 inhibitors decrease cardiovascular death and events in patients with diabetes have attracted attention in the cardiology field. We conducted a study of canagliflozin in patients with chronic heart failure and type II diabetes. Thirty-five Japanese patients with chronic heart failure and type II diabetes were treated with canagliflozin for 12 months. The primary endpoints were the changes of subcutaneous, visceral, and total fat areas at 12 months determined by computed tomography. Secondary endpoints included markers of glycemic control, renal function, and oxidative stress, as well as lipid parameters, atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), flow-mediated dilation (FMD), and echocardiographic left ventricular function. All fat areas (subcutaneous, visceral, and total) showed a significant decrease at 12 months. ANP and BNP also decreased significantly, along with improvement of renal function, oxidized LDL, and E/e', FMD increased significantly after canagliflozin treatment. Canagliflozin demonstrated cardiac and renal protective effects as well as improving oxidative stress, diastolic function, and endothelial function. This drug was effective in patients who had heart failure with preserved ejection fraction and could become first-line therapy for such patients with diabetes. Trial registration UMIN ( http://www.umin.ac.jp/ ), Study ID: UMIN000021239.
Sections du résumé
BACKGROUND
Reports that sodium glucose cotransporter 2 inhibitors decrease cardiovascular death and events in patients with diabetes have attracted attention in the cardiology field. We conducted a study of canagliflozin in patients with chronic heart failure and type II diabetes.
METHODS
Thirty-five Japanese patients with chronic heart failure and type II diabetes were treated with canagliflozin for 12 months. The primary endpoints were the changes of subcutaneous, visceral, and total fat areas at 12 months determined by computed tomography. Secondary endpoints included markers of glycemic control, renal function, and oxidative stress, as well as lipid parameters, atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), flow-mediated dilation (FMD), and echocardiographic left ventricular function.
RESULTS
All fat areas (subcutaneous, visceral, and total) showed a significant decrease at 12 months. ANP and BNP also decreased significantly, along with improvement of renal function, oxidized LDL, and E/e', FMD increased significantly after canagliflozin treatment.
CONCLUSION
Canagliflozin demonstrated cardiac and renal protective effects as well as improving oxidative stress, diastolic function, and endothelial function. This drug was effective in patients who had heart failure with preserved ejection fraction and could become first-line therapy for such patients with diabetes. Trial registration UMIN ( http://www.umin.ac.jp/ ), Study ID: UMIN000021239.
Identifiants
pubmed: 31167663
doi: 10.1186/s12933-019-0877-2
pii: 10.1186/s12933-019-0877-2
pmc: PMC6551875
doi:
Substances chimiques
Biomarkers
0
Blood Glucose
0
Sodium-Glucose Transporter 2 Inhibitors
0
Canagliflozin
0SAC974Z85
Natriuretic Peptide, Brain
114471-18-0
Atrial Natriuretic Factor
85637-73-6
Banques de données
JPRN
['UMIN000021239']
Types de publication
Controlled Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
76Références
Cardiovasc Diabetol. 2018 Sep 27;17(1):129
pubmed: 30261876
Cardiovasc Diabetol. 2016 Jul 15;15:97
pubmed: 27422625
Cardiovasc Diabetol. 2017 Mar 3;16(1):32
pubmed: 28253918
N Engl J Med. 2019 Jan 24;380(4):347-357
pubmed: 30415602
N Engl J Med. 2016 Jul 28;375(4):323-34
pubmed: 27299675
PLoS One. 2014 Jun 24;9(6):e100777
pubmed: 24960177
BMC Cardiovasc Disord. 2017 Aug 23;17(1):229
pubmed: 28835229
N Engl J Med. 2017 Aug 17;377(7):644-657
pubmed: 28605608
N Engl J Med. 2015 Nov 26;373(22):2117-28
pubmed: 26378978
Circ J. 2018 Jun 25;82(7):1752-1753
pubmed: 29877204
Eur J Heart Fail. 2017 Nov;19(11):1390-1400
pubmed: 28836359
Lancet. 2013 Sep 14;382(9896):941-50
pubmed: 23850055
Cardiovasc Diabetol. 2017 Oct 12;16(1):130
pubmed: 29025406
Eur J Heart Fail. 2018 Dec;20(12):1690-1700
pubmed: 30328645
Adv Ther. 2017 Feb;34(2):436-451
pubmed: 27981497
Front Cardiovasc Med. 2016 Oct 26;3:43
pubmed: 27833913
Diabetol Metab Syndr. 2017 Oct 4;9:78
pubmed: 29034006
Cardiovasc Drugs Ther. 2017 Jun;31(3):233-246
pubmed: 28643218
Cardiovasc Diabetol. 2017 Jul 6;16(1):84
pubmed: 28683796
Cardiovasc Diabetol. 2018 Oct 8;17(1):132
pubmed: 30296931
Int J Mol Sci. 2019 Feb 01;20(3):
pubmed: 30717173
Cardiovasc Diabetol. 2018 May 22;17(1):73
pubmed: 29788955
Lancet Diabetes Endocrinol. 2018 Sep;6(9):691-704
pubmed: 29937267
Circ J. 2017 Jan 25;81(2):155-157
pubmed: 28111376
Kidney Int. 2016 Mar;89(3):524-6
pubmed: 26880444
Circulation. 2019 May 28;139(22):2528-2536
pubmed: 30882238
Endocr J. 2016 Jun 30;63(6):589-96
pubmed: 27052123
Endocr J. 2018 Aug 27;65(8):859-867
pubmed: 29806620